



SAFETY DATA SHEET

Revision date 22-Aug-2023

Version 2

Page 1 / 13

Section 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

1.1. Product identifier

Product Name Furosemide Injection (Hospira, Inc.)
Product Code(s) PZ03379
Trade Name: Not applicable
Chemical Family: Not determined

1.2. Relevant identified uses of the substance or mixture and uses advised against

Recommended Use Pharmaceutical product

1.3. Details of the supplier of the safety data sheet

Hospira, A Pfizer Company
275 North Field Drive
Lake Forest, Illinois 60045
1-800-879-3477

Pfizer Ireland Pharmaceuticals
OSG Building
Ringaskiddy, Co. Cork.
Ireland
+353 21 4378701

E-mail address pfizer-MSDS@pfizer.com

1.4. Emergency telephone number

Emergency Telephone Chemtrec 1-800-424-9300 International Chemtrec (24 hours):+1-703-527-3887

Section 2: HAZARDS IDENTIFICATION

2.1. Classification of the substance or mixture

GHS - Classification: Regulated according to Regulation (EC) 1272/2008 and/or other applicable regulations.

Reproductive toxicity Category 2 - (H361d)

2.2. Label elements

Signal word Warning

Hazard statements H361d - Suspected of damaging the unborn child

Precautionary Statements P201 - Obtain special instructions before use
P202 - Do not handle until all safety precautions have been read and understood
P281 - Use personal protective equipment as required

SAFETY DATA SHEET

Product Name Furosemide Injection (Hospira, Inc.)
Revision date 22-Aug-2023

Page 2 / 13
Version 2

P308 + P313 - IF exposed or concerned: Get medical attention/advice
P405 - Store locked up
P501 - Dispose of contents/container in accordance with all local and national regulations



2.3. Other hazards

Other hazards

An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

Note:

This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

Section 3: COMPOSITION/INFORMATION ON INGREDIENTS

3.1 Substances

Substances

Not applicable

3.2 Mixtures

Hazardous

Chemical name	Weight-%	REACH Registration Number	EC No	Classification according to Regulation (EC) No. 1272/2008 [CLP]	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)
Furosemide (CAS #: 54-31-9)	1		200-203-6	Repr.2 (H361d)	Not Listed	No data available	No data available
Sodium hydroxide (CAS #: 1310-73-2)	<1	-	215-185-5	Skin Corr.1A (H314)	Eye Irrit. 2 :: 0.5%<=C<2% Skin Corr. 1A :: C>=5% Skin Corr. 1B :: 2%<=C<5% Skin Irrit. 2 :: 0.5%<=C<2%	No data available	No data available
+ Hydrochloric Acid (CAS #: 7647-01-0)	**	-	231-595-7	Acute Tox. 3 (H331) Skin Corr. 1A (H314) Press. Gas	Eye Irrit. 2 :: 10%<=C<25% Skin Corr. 1B :: C>=25% Skin Irrit. 2 :: 10%<=C<25% STOT SE 3 :: C>=10%	No data available	No data available

NonHazardous

Chemical name	Weight-%	REACH Registration Number	EC No	Classification according to Regulation	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)

SAFETY DATA SHEET

Product Name Furosemide Injection (Hospira, Inc.)
Revision date 22-Aug-2023

Page 3 / 13
Version 2

				(EC) No. 1272/2008 [CLP]			
Water (CAS #: 7732-18-5)	*	-	231-791-2	Not classified as hazardous	Not Listed	No data available	No data available
SODIUM CHLORIDE (CAS #: 7647-14-5)	*	-	231-598-3	Not classified as hazardous	Not Listed	No data available	No data available

Full text of H- and EUH-phrases: see section 16

Acute Toxicity Estimate

Chemical name	Oral LD50	Dermal LD50	Inhalation LC50 - 4 hour - dust/mist - mg/L	Inhalation LC50 - 4 hour - vapor - mg/L	Inhalation LC50 - 4 hour - gas - ppm
Water 7732-18-5	89838.9	No data available	No data available	No data available	No data available
Furosemide 54-31-9	4600	No data available	No data available	No data available	No data available
SODIUM CHLORIDE 7647-14-5	3000	10000	No data available	No data available	No data available
Sodium hydroxide 1310-73-2	325	1350	No data available	No data available	No data available
+ Hydrochloric Acid 7647-01-0	238	5010	No data available	No data available	563.3022

Additional information

* Proprietary

** to adjust pH

Non-hazardous ingredients provided for completeness. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret. Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

Section 4: FIRST AID MEASURES

4.1. Description of first aid measures

Inhalation	Remove to fresh air. Seek immediate medical attention/advice.
Eye contact	Rinse thoroughly with plenty of water for at least 15 minutes, lifting lower and upper eyelids. Consult a physician.
Skin contact	Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.
Ingestion	Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

4.2. Most important symptoms and effects, both acute and delayed

Most important symptoms and effects For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

4.3. Indication of any immediate medical attention and special treatment needed

SAFETY DATA SHEET

Product Name Furosemide Injection (Hospira, Inc.)
Revision date 22-Aug-2023

Page 4 / 13
Version 2

Note to physicians None.

Section 5: FIRE-FIGHTING MEASURES

5.1. Extinguishing media

Suitable Extinguishing Media Dry chemical, CO₂, alcohol-resistant foam or water spray.

5.2. Special hazards arising from the substance or mixture

Specific hazards arising from the chemical Fine particles (such as mists) may fuel fires/explosions.

Hazardous combustion products May include oxides of nitrogen and sulfur and products of chlorine

5.3. Advice for firefighters

Special protective equipment for fire-fighters Firefighters should wear self-contained breathing apparatus and full firefighting turnout gear. Use personal protection equipment.

Section 6: ACCIDENTAL RELEASE MEASURES

6.1. Personal precautions, protective equipment and emergency procedures

Personal precautions Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

For emergency responders Use personal protection recommended in Section 8.

6.2. Environmental precautions

Environmental precautions Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

6.3. Methods and material for containment and cleaning up

Methods for containment Prevent further leakage or spillage if safe to do so.

Methods for cleaning up Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.

Prevention of secondary hazards Clean contaminated objects and areas thoroughly observing environmental regulations.

6.4. Reference to other sections

Reference to other sections See section 8 for more information. See section 13 for more information.

Section 7: HANDLING AND STORAGE

7.1. Precautions for safe handling

Advice on safe handling

Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

General hygiene considerations Handle in accordance with good industrial hygiene and safety practice.

7.2. Conditions for safe storage, including any incompatibilities

Storage Conditions Store as directed by product packaging.

SAFETY DATA SHEET

Product Name Furosemide Injection (Hospira, Inc.)
Revision date 22-Aug-2023

Page 5 / 13
Version 2

7.3. Specific end use(s)

Specific use(s) Pharmaceutical drug product.

Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1. Control parameters

Exposure Limits

Refer to available public information for specific member state Occupational Exposure Limits.

Furosemide

Pfizer OEL TWA-8 Hr: 40 µg/m³

SODIUM CHLORIDE

Latvia 5 mg/m³
Russia MAC: 5 mg/m³

Sodium hydroxide

ACGIH OEL (Ceiling) 2 mg/m³
ACGIH TLV Ceiling: 2 mg/m³
Austria 2 mg/m³
STEL 4 mg/m³
Bulgaria 2.0 mg/m³
Czech Republic 1 mg/m³
Ceiling: 2 mg/m³
Denmark Ceiling: 2 mg/m³
Estonia 1 mg/m³
STEL: 2 mg/m³
Finland Ceiling: 2 mg/m³
France 2 mg/m³
Hungary 1 mg/m³
STEL: 2 mg/m³
Ireland STEL: 2 mg/m³
Ceiling Limit Value 2 mg/m³
Latvia 0.5 mg/m³
Poland STEL: 1 mg/m³
0.5 mg/m³
Romania 1 mg/m³
STEL: 3 mg/m³
Slovakia 2 mg/m³
Spain STEL: 2 mg/m³
Switzerland 2 mg/m³
STEL: 2 mg/m³
OSHA PEL 2 mg/m³
(vacated) Ceiling: 2 mg/m³
STEL: 2 mg/m³
United Kingdom STEL: 2 mg/m³

+ Hydrochloric Acid

ACGIH OEL (Ceiling) 2 ppm
ACGIH TLV Ceiling: 2 ppm
Austria 5 ppm
8 mg/m³
STEL 10 ppm
STEL 15 mg/m³
Bulgaria STEL: 10 ppm
STEL: 15.0 mg/m³
5 ppm
8.0 mg/m³
Czech Republic 8 mg/m³
Ceiling: 15 mg/m³
Estonia 5 ppm

SAFETY DATA SHEET

Product Name Furosemide Injection (Hospira, Inc.)
Revision date 22-Aug-2023

Page 6 / 13
Version 2

	8 mg/m ³
	STEL: 10 ppm
	STEL: 15 mg/m ³
European Union	TWA: 5 ppm
	TWA: 8 mg/m ³
	STEL: 10 ppm
	STEL: 15 mg/m ³
Finland	STEL: 5 ppm
	STEL: 7.6 mg/m ³
Germany	2 ppm
	3.0 mg/m ³
	Ceiling / Peak: 4 ppm
	Ceiling / Peak: 6 mg/m ³
Germany	2 ppm
	3 mg/m ³
Hungary	8 mg/m ³
	STEL: 16 mg/m ³
Ireland	8 mg/m ³
	5 ppm
	STEL: 10 ppm
	STEL: 15 mg/m ³
Italy	5 ppm
	8 mg/m ³
	STEL: 10 ppm
	STEL: 15 mg/m ³
Ceiling Limit Value	2 ppm
	3.0 mg/m ³
Latvia	5 ppm
	8 mg/m ³
	STEL: 10 ppm
	STEL: 15 mg/m ³
Netherlands	8 mg/m ³
	STEL: 15 mg/m ³
Poland	STEL: 10 mg/m ³
	5 mg/m ³
Romania	5 ppm
	8 mg/m ³
	STEL: 10 ppm
	STEL: 15 mg/m ³
Russia	MAC: 5 mg/m ³
Slovakia	5 ppm
	8.0 mg/m ³
Spain	5 ppm
	7.6 mg/m ³
	STEL: 10 ppm
	STEL: 15 mg/m ³
Switzerland	2 ppm
	3 mg/m ³
	STEL: 4 ppm
	STEL: 6 mg/m ³
U.S. - OSHA - Final PELs - Ceiling Limits	5 ppm
	7 mg/m ³
OSHA PEL	(vacated) Ceiling: 5 ppm
	(vacated) Ceiling: 7 mg/m ³
	Ceiling: 5 ppm
	Ceiling: 7 mg/m ³
United Kingdom	TWA: 1 ppm
	TWA: 2 mg/m ³
	STEL: 5 ppm
	STEL: 8 mg/m ³

SAFETY DATA SHEET

Product Name Furosemide Injection (Hospira, Inc.)
Revision date 22-Aug-2023

Page 7 / 13
Version 2

SODIUM CHLORIDE

Pfizer Occupational Exposure Band (OEB): OEB 1 (control exposure to the range of 1000ug/m³ to 3000ug/m³)

8.2. Exposure controls

Engineering controls	Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.
Environmental exposure controls	No information available.
Personal protective equipment	Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.
Eye/face protection	Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.).
Hand protection	Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.).
Skin and body protection	Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.).
Respiratory protection	Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international equivalent.).
General hygiene considerations	Handle in accordance with good industrial hygiene and safety practice.

Section 9: PHYSICAL AND CHEMICAL PROPERTIES

9.1. Information on basic physical and chemical properties

Physical state	Solution
Color	Clear, colorless
Odor	No information available.
Odor threshold	No information available
Molecular formula	Mixture
Molecular weight	Mixture
Property	Values
pH	9.0 (8.0-9.3)
Melting point / freezing point	No data available
Boiling point / boiling range	
Flash point	No information available
Evaporation rate	No data available
Flammability (solid, gas)	No data available
Flammability Limit in Air	
Upper flammability limit:	No data available
Lower flammability limit:	No data available

SAFETY DATA SHEET

Product Name Furosemide Injection (Hospira, Inc.)
Revision date 22-Aug-2023

Page 8 / 13
Version 2

Vapor pressure	No data available
Vapor density	No data available
Relative density	No data available
Water solubility	No data available
Solubility(ies)	No data available
Partition coefficient	No data available
Autoignition temperature	No data available
Decomposition temperature	No data available
Kinematic viscosity	No data available
Dynamic viscosity	No data available
Particle characteristics	
Particle Size	No information available
Particle Size Distribution	No information available
Explosive properties	No information available

Partition Coefficient: (Method, pH, Endpoint, Value)

Furosemide
Predicted 7.4 Log D -0.776

9.2. Other information

No information available

9.2.1. Information with regard to physical hazard classes

No information available

9.2.2. Other safety characteristics

No information available

Section 10: STABILITY AND REACTIVITY

10.1. Reactivity

Reactivity No data available.

10.2. Chemical stability

Stability Stable at normal conditions.

Explosion data

Sensitivity to Mechanical Impact No data available.

Sensitivity to Static Discharge No data available.

10.3. Possibility of hazardous reactions

Possibility of hazardous reactions No information available.

Hazardous polymerization No data available.

10.4. Conditions to avoid

Conditions to avoid Fine particles (such as mists) may fuel fires/explosions.

10.5. Incompatible materials

Incompatible materials As a precautionary measure, keep away from strong oxidizers.

10.6. Hazardous decomposition products

Hazardous decomposition products No data available.

Section 11: TOXICOLOGICAL INFORMATION

11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008

Short term Ingestion may cause lowering of blood pressure. Accidental or incidental ingestion of large amounts may cause nausea, abdominal discomfort, headache or dizziness. Individuals

SAFETY DATA SHEET

Product Name Furosemide Injection (Hospira, Inc.)
Revision date 22-Aug-2023

Page 9 / 13
Version 2

<p>Acute toxicity</p> <p>Serious eye damage/eye irritation</p> <p>Skin corrosion/irritation</p> <p>Respiratory or skin sensitization</p> <p>STOT - single exposure</p> <p>STOT - repeated exposure</p> <p>Reproductive toxicity</p> <p>Germ cell mutagenicity</p> <p>Carcinogenicity</p> <p>Aspiration hazard</p>	<p>sensitive to this chemical or other materials in its chemical class may develop allergic reactions.</p> <p>Based on available data, the classification criteria are not met.</p> <p>Based on available data, the classification criteria are not met.</p> <p>Based on available data, the classification criteria are not met.</p> <p>Based on available data, the classification criteria are not met.</p> <p>Based on available data, the classification criteria are not met.</p> <p>Based on available data, the classification criteria are not met.</p> <p>Suspected of damaging the unborn child. Classification is based on mixture calculation methods based on component data.</p> <p>Based on available data, the classification criteria are not met.</p> <p>Based on available data, the classification criteria are not met.</p> <p>Based on available data, the classification criteria are not met.</p>
--	--

Acute Toxicity: (Species, Route, End Point, Dose)

Furosemide

Rat Oral LD 50 4600 mg/kg
 Mouse Sub-tenon injection (eye) Minimum Symptomatic Dose 400 mg/kg
 Mouse Oral LD50 1000 mg/kg

SODIUM CHLORIDE

Rat Sub-tenon injection (eye) LC50/1hr > 42 g/m³
 Rat Oral LD 50 3 g/kg
 Mouse Oral LD 50 4 g/kg
 Rabbit Dermal LD 50 > 10 g/kg

Sodium hydroxide

Mouse IP LD50 40 mg/kg

Chemical name	Oral LD50	Dermal LD50	Inhalation LC50
Water	> 90 mL/kg (Rat)	-	-
Furosemide	= 2600 mg/kg (Rat)	-	-
SODIUM CHLORIDE	= 3 g/kg (Rat)	> 10000 mg/kg (Rabbit)	> 42 mg/L (Rat) 1 h
Sodium hydroxide	= 325 mg/kg (Rat)	= 1350 mg/kg (Rabbit)	-
+ Hydrochloric Acid	238 - 277 mg/kg (Rat)	> 5010 mg/kg (Rabbit)	= 1.68 mg/L (Rat) 1 h

Irritation / Sensitization: (Study Type, Species, Severity)

SODIUM CHLORIDE

Skin irritation Rabbit Mild
 Eye irritation Rabbit Mild

Sodium hydroxide

Eye Irritation Rabbit Severe
 Skin Irritation Rabbit Severe

+ Hydrochloric Acid

Skin irritation Severe
 Eye irritation Severe

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Furosemide

13 Week(s) Rat Oral 300 mg/kg LOAEL
 13 Week(s) Mouse Oral 600 mg/kg LOAEL
 6 Month(s) Dog Oral 10 mg/kg/day LOAEL Kidney
 2 Year(s) Rat Oral 30 mg/kg/day LOAEL
 13 Week(s) Mouse Oral, in feed (M) 938 / (F) 625 mg/kg/day LOAEL Liver
 3 Month(s) Monkey Oral Dose not specified Kidney, Bone Marrow, Skeletal muscle
 1 Year(s) Monkey Oral 27 mg/kg/day LOAEL Kidney

SAFETY DATA SHEET

Product Name Furosemide Injection (Hospira, Inc.)
Revision date 22-Aug-2023

Page 10 / 13
Version 2

1 Year(s) Rat Oral 50 mg/kg/day LOEL Heart, Blood, Kidney

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Furosemide

Reproductive & Fertility Rat Oral 2.9 mg/kg/day LOEL Fertility
Embryo / Fetal Development Rabbit Oral 25 mg/kg LOEL Maternal Toxicity, Fetotoxicity
Embryo / Fetal Development Rabbit Oral 12.5 mg/kg/day LOEL Teratogenic
Embryo / Fetal Development Mouse Oral 1250 mg/kg/day LOEL Fetotoxicity, Teratogenic

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Furosemide

Bacterial Mutagenicity (Ames) *Salmonella* Negative
In Vitro Micronucleus Human Lymphocytes Positive
Mammalian Cell Mutagenicity Mouse Lymphoma Positive
In Vivo Chromosome Aberration Hamster Bone Marrow Negative

+ Hydrochloric Acid

Bacterial Mutagenicity (Ames) *Salmonella* Negative
In Vivo Micronucleus Rat Negative

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Furosemide

2 Year(s) Male Rat Oral 15 mg/kg/day LOEL Tumors
104 Month(s) Mouse Female Oral 17.5 LOEL Tumors
2 Year(s) Female Rat Oral, in feed 700 ppm NOEL Not carcinogenic
104 Month(s) Male Mouse Oral, in feed 1400 ppm NOEL Not carcinogenic

Carcinogenicity None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

Furosemide

IARC Group 3 (Not Classifiable)

+ Hydrochloric Acid

IARC Group 3 (Not Classifiable)

11.2. Information on other hazards

11.2.1. Endocrine disrupting properties

Endocrine disrupting properties No information available.

11.2.2. Other information

Other adverse effects No information available.

Section 12: ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been thoroughly investigated. Releases to the environment should be avoided.

12.1. Toxicity

No information available

12.2. Persistence and degradability

Persistence and degradability No information available.

12.3. Bioaccumulative potential

Bioaccumulation

SAFETY DATA SHEET

Product Name Furosemide Injection (Hospira, Inc.)
Revision date 22-Aug-2023

Page 11 / 13
Version 2

Partition Coefficient: (Method, pH, Endpoint, Value)

Furosemide

Predicted 7.4 Log D -0.776

12.4. Mobility in soil

Mobility in soil No information available.

12.5. Results of PBT and vPvB assessment

PBT and vPvB assessment

Chemical name	PBT and vPvB assessment
SODIUM CHLORIDE	The substance is not PBT / vPvB PBT assessment does not apply
Sodium hydroxide	The substance is not PBT / vPvB PBT assessment does not apply
+ Hydrochloric Acid	The substance is not PBT / vPvB PBT assessment does not apply

12.6. Endocrine disrupting properties

Endocrine disrupting properties No information available.

12.7. Other adverse effects

No information available.

Section 13: DISPOSAL CONSIDERATIONS

13.1. Waste treatment methods

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural wastewater and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

Section 14: TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

This material is not regulated for transportation / carriage.

UN number: Not applicable
UN proper shipping name: Not applicable
Transport hazard class(es): Not applicable
Packing group: Not applicable
Environmental Hazard(s): Not applicable

Special precautions for user: Not applicable

SAFETY DATA SHEET

Product Name Furosemide Injection (Hospira, Inc.)
Revision date 22-Aug-2023

Page 12 / 13
Version 2

Section 15: REGULATORY INFORMATION

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

Water

CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
TSCA	Present
EINECS	231-791-2
AICS	Present

Furosemide

CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
EINECS	200-203-6
Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)	Schedule 4

SODIUM CHLORIDE

CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
TSCA	Present
EINECS	231-598-3
AICS	Present

Sodium hydroxide

CERCLA/SARA Section 313 de minimus %	Not Listed
Hazardous Substances RQs	1000 lb
California Proposition 65	Not Listed
TSCA	Present
EINECS	215-185-5
AICS	Present
Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)	Schedule 5 Schedule 6

+ Hydrochloric Acid

CERCLA/SARA Section 313 de minimus %	1.0 %
Hazardous Substances RQs	5000 lb
California Proposition 65	Not Listed
TSCA	Present
EINECS	231-595-7
AICS	Present
Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)	Schedule 5 Schedule 6

France

Occupational Illnesses (R-463-3, France)

Chemical name	French RG number	Title
SODIUM CHLORIDE 7647-14-5	RG 78	-

European Union

Take note of Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work

Authorizations and/or restrictions on use:

This product contains one or more substance(s) subject to restriction (Regulation (EC) No. 1907/2006 (REACH), Annex XVII)

Chemical name	Restricted substance per REACH Annex XVII	Substance subject to authorization per REACH Annex XIV
Sodium hydroxide - 1310-73-2	Use restricted. See item 75.	
+ Hydrochloric Acid - 7647-01-0	Use restricted. See item 75.	

Persistent Organic Pollutants

SAFETY DATA SHEET

Product Name Furosemide Injection (Hospira, Inc.)
Revision date 22-Aug-2023

Page 13 / 13
Version 2

Not applicable

Ozone-depleting substances (ODS) regulation (EC) 1005/2009

Not applicable

Named dangerous substances per Seveso Directive (2012/18/EU)

Chemical name	Lower-tier requirements (tons)	Upper-tier requirements (tons)
+ Hydrochloric Acid - 7647-01-0	25	250

Plant protection products directive (91/414/EEC)

Chemical name	Plant protection products directive (91/414/EEC)
SODIUM CHLORIDE - 7647-14-5	Plant protection agent

EU - Biocides

Chemical name	EU - Biocides
+ Hydrochloric Acid - 7647-01-0	Product-type 2: Disinfectants and algacides not intended for direct application to humans or animals

Legend:

TSCA - United States Toxic Substances Control Act Section 8(b) Inventory

EINECS/ELINCS - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances

AICS - Australian Inventory of Chemical Substances

15.2. Chemical safety assessment

Chemical Safety Report No information available

Section 16: OTHER INFORMATION

Key or legend to abbreviations and acronyms used in the safety data sheet

Full text of H-Statements referred to under section 3

Reproductive toxicity-Cat.2; H361d - Suspected of damaging the unborn child. Skin corrosion/irritation-Cat.1A; H314 - Causes severe skin burns and eye damage. Acute toxicity, dermal-Cat.3; H311 - Toxic in contact with skin.

Data Sources: Pfizer proprietary drug development information. Publicly available toxicity information.

Reason for revision Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 11 - Toxicology Information. Updated Section 12 - Ecological Information. Updated Section 15 - Regulatory Information. Updated Section 16 - Other Information.

Revision date 22-Aug-2023

Prepared By Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.